Assertio (NASDAQ:ASRT) Reports Quarterly Earnings, Falls Short of Expectations

Assertio (NASDAQ:ASRT) announced its quarterly earnings results on Wednesday, revealing an earnings per share (EPS) of ($0.11). This figure was below analysts' expectations of ($0.05), resulting in a miss of $0.06 per share, as reported by Zacks.

The company demonstrated a return on equity of 3.79%, though it also reported a net margin of -54.46%. In light of its performance, Assertio has also updated its fiscal year 2025 guidance for EPS.

Assertio Stock Movement

During mid-day trading on Wednesday, shares of Assertio saw an increase of 0.7%, rising by $0.01 to reach $0.78. Approximately 278,215 shares were traded, which is less than the average volume of 816,829 shares. Currently, Assertio's 50-day moving average is $0.82, and its 200-day moving average stands at $0.97. The company shows a debt-to-equity ratio of 0.30, alongside a quick ratio of 1.57 and a current ratio of 2.01. Assertio's stock has seen a 52-week low of $0.73 and a high of $1.80. With a market capitalization of $74.34 million, its price-to-earnings (PE) ratio is -1.07, and the price-to-earnings-growth (PEG) ratio is 3.25. The stock has a beta of 0.81.

Price Targets Set by Analysts

Several research firms have recently provided input on Assertio. StockNews.com upgraded the company's rating from "hold" to "buy" as of November 13th. Additionally, HC Wainwright reaffirmed its "buy" rating and set a price target of $4.00 for Assertio shares on December 16th.

About Assertio

Assertio Holdings, Inc. is a commercial pharmaceutical company that supplies a range of products to patients in the United States. Its portfolio includes drugs like INDOCIN, which is available in oral and suppository forms. This medication is primarily used for treating moderate to severe rheumatoid arthritis, acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, painful shoulder, and gouty arthritis.

Considerations for Investors

Before making any investment in Assertio, potential investors should conduct thorough research. Market analysts are actively recommending a selection of stocks that may present better investment opportunities compared to Assertio. Reports indicate that while Assertio is currently rated as a "buy," top analysts believe there are at least five other stocks that might be more favorable choices for investment.

Investors should consider exploring these recommendations to ensure they are making informed decisions.

earnings, stocks, finance